GenFleet Therapeutics Completes HK$9.34 Million Share Buyback, Trimming Free Float by 0.13%

Bulletin Express11-02

GenFleet Therapeutics (Shanghai) Inc. repurchased 450,000 H shares on 2 November 2026, spending HK$9.34 million at prices ranging from HK$20.56 to HK$21.06 per share. The volume-weighted average repurchase price was HK$20.76 per share.

Following the transaction, the company’s outstanding share count (excluding treasury shares) declined to 349.04 million, down 0.13% from 349.49 million prior to the buyback. Treasury shares increased to 2.59 million, while the total issued share capital remained unchanged at 351.63 million shares.

The repurchase was executed on the Hong Kong Stock Exchange under the mandate approved by shareholders on 11 May 2026, which authorises the company to buy back up to 37.04 million shares. Cumulative buybacks under this mandate now total 2.59 million shares, representing 0.70% of the company’s issued shares on the mandate date.

In accordance with Hong Kong listing rules, GenFleet is subject to a moratorium on issuing, selling or transferring any new or treasury shares until 2 December 2026. The company confirmed that the repurchase complied with all relevant regulatory requirements and that all applicable funds had been duly settled.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment